WO2005073729A3 - Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11) - Google Patents

Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11) Download PDF

Info

Publication number
WO2005073729A3
WO2005073729A3 PCT/EP2005/000470 EP2005000470W WO2005073729A3 WO 2005073729 A3 WO2005073729 A3 WO 2005073729A3 EP 2005000470 W EP2005000470 W EP 2005000470W WO 2005073729 A3 WO2005073729 A3 WO 2005073729A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
therapeutics
diagnostics
protein
diseases associated
Prior art date
Application number
PCT/EP2005/000470
Other languages
English (en)
Other versions
WO2005073729A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005073729A2 publication Critical patent/WO2005073729A2/fr
Publication of WO2005073729A3 publication Critical patent/WO2005073729A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un récepteur P2Y11 humain lequel est associé aux maladies dermatologiques, endocriniennes, métaboliques, gastro-entérologiques, aux cancers, aux inflammations, aux maladies cardiovasculaires, hématologiques, respiratoires, neurologiques et urologiques. L'invention concerne en outre des procédés d'analyse permettant d'identifier des composés pouvant servir au traitement ou à la prévention des maladies dermatologiques, endocriniennes, métaboliques, gastro-entérologiques, des cancers, des inflammations, des maladies hématologiques, respiratoires, neurologiques et urologiques. L'invention concerne en outre des composés qui se lient à P2Y11 et ou activent ou inhibent l'activité de ce dernier, ainsi que des compositions pharmaceutiques contenant de tels composés.
PCT/EP2005/000470 2004-01-31 2005-01-19 Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11) WO2005073729A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002140 2004-01-31
EP04002140.4 2004-01-31

Publications (2)

Publication Number Publication Date
WO2005073729A2 WO2005073729A2 (fr) 2005-08-11
WO2005073729A3 true WO2005073729A3 (fr) 2005-12-08

Family

ID=34814232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/000470 WO2005073729A2 (fr) 2004-01-31 2005-01-19 Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)

Country Status (1)

Country Link
WO (1) WO2005073729A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136336A1 (fr) * 2006-05-19 2007-11-29 Forskarpatent I Syd Ab Diagnostic du risque accru d'infarctus aigu du myocarde
DE102006037920A1 (de) * 2006-08-11 2008-02-14 Rheinische Friedrich-Wilhelms Universität Spezielle Carbonylbisimino-Verbindungen zur Behandlung von Immunerkrankungen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOEYNAEMS J M: "overview of P2Y receptors as therapeutic targets", DRUG DEVELOPMENT RESEARCH, vol. 52, 2001, pages 187 - 189, XP002325018 *
COMMUNI D ET AL: "Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenyl cyclase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 51, 19 December 1997 (1997-12-19), pages 31969 - 31973, XP002083513, ISSN: 0021-9258 *
COMMUNI^A D ET AL: "Rapid up-regulation of P2Y messengers during granulocytic differentiation of HL-60 cells", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 475, no. 1, 9 June 2000 (2000-06-09), pages 39 - 42, XP004337229, ISSN: 0014-5793 *
JANSSENS R ET AL: "Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 132, no. 2, January 2001 (2001-01-01), pages 536 - 546, XP002973033, ISSN: 0007-1188 *
WANG L: "P2 receptor expression profiles in human vascular smooth muscle and endothelial cells", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 40, 2002, pages 841 - 853, XP008019699 *
WEYDEN L: "pharmacological characterisation of the p2y11 receptors in stabily transfected haematological cell lines", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 213, 2000, pages 75 - 81, XP002325019 *

Also Published As

Publication number Publication date
WO2005073729A2 (fr) 2005-08-11

Similar Documents

Publication Publication Date Title
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2006005469A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2005100990A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
WO2005076007A3 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2006021343A3 (fr) Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a)
WO2005101001A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur couple a la proteine g, element c, groupe 5, famille c (gprc5c)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2005113788A3 (fr) Diagnostics et therapeutiques pour des maladies associees a la kinase 6 associee au recepteur couple a une proteine g (grk6)
WO2006013013A3 (fr) Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb)
WO2006005470A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au recepteur couple a la proteine g lie au mas (mrge)
WO2005095953A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 6 (ccr6)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2005101011A3 (fr) Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra)
WO2005119263A3 (fr) Diagnostic et traitement des maladies associees au recepteur couple aux proteines g 92 (gpr92)
WO2005075990A3 (fr) Diagnostics et therapeutiques pour maladies associees au recepteur nucleaire humain nr4a2 (nr4a2)
WO2006005461A3 (fr) Diagnostic et traitement des maladies associees au recepteur 27 couple aux proteines g (rcpg 27)
WO2005101006A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur beta du retinoide x (rxrb)
WO2005040791A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr)
WO2005093426A3 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur d'acide retinoique alpha (rara)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase